Watch elite gamers face off in League of Legends. Photo by Jamie McInall/Pexels

Heads up, gamers. The most popular esport is coming to the Bayou City. The League Championship Series (LCS), will host its marquee championship event at NRG Stadium (8825 Kirby Dr.) on April 23 and 24, the organization announced.

Not only is this the first time the tournament will be held in Texas, it’s also the first time the prestigious League of Legends competition — the LCS Spring Finals — will be hosted in an NFL stadium. For the uninitiated, League of Legends is a wildly popular, team-based multiplayer strategy game.

Houston fans are invited to attend both the pregame Fan Fest celebration and the LCS Finals, a first since the pandemic. The Fan Fest starts at 10 am Saturday, April 23, and the first match starts at 2:30 pm.

As the league’s first seasonal championship event of the year, the competition will see North America’s top three teams vie for an LCS trophy, a banner in the LCS Studio rafters, and an invite to the international Mid-Season Invitational in Busan, South Korea next month, per a release.

Developed and run by influential and prolific developer and publisher Riot Games, this championship will be held in North America across four cities — Mexico City, New York City, Toronto and San Francisco, a first since 2016, a release notes.

As the most-watched esport in the world with 12 international leagues, the 10-year-old LCS is actually the third-most popular major professional sports league among 18- to 34-year-olds in the U.S., per industry insiders.

For some perspective, more than 465 million people watched esports in 2021. Esports generated more than $1 billion in revenue, according to a Newzoo report.

For more information on the Fan Fest and tournament, visit the official site.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”